α-Vitamin E (Synonyms:D-α-生育酚; (+)-α-Tocopherol; D-α-Tocopherol)
目录号 : KM19992 CAS No. : 59-02-9 纯度 : 98%

α-Vitamin E ((+)-α-Tocopherol) 是一种天然存在的维生素 E,是一种有效的抗氧化剂。

规格 价格 是否有货 数量
100mg
In-stock
1g
In-stock
5g 询价 In-stock
10g 询价 In-stock

Other Forms of Rapamycin:

KKL Med 的所有产品和服务仅用于科学研究,不能被用于人体,兽医,我们也不向个人提供产品和服务。
生物活性

α-Vitamin E ((+)-α-Tocopherol), a naturally occurring vitamin E form, is a potent antioxidant.

体外研究

α-Vitamin E ((+)-α-Tocopherol) is a peroxyl radical scavenger. The importance of this function is to maintain the integrity of long-chain polyunsaturated fatty acids in the membranes of cells and thus maintain their bioactivity.
α-Vitamin E ((+)-α-Tocopherol) has been described to inhibit PKC in various cell types with consequent inhibition of platelet aggregation, endothelial cell nitric oxide production and superoxide production in neutrophils and macrophages. α-Vitamin E ((+)-α-Tocopherol) exposure induced the activation of both the MAP kinase and PI3 kinase (PI3K) pathways, suggesting that it is the oxidative stress that up-regulates kinase pathways and the antioxidant action of α-tocopherol protects the cell membrane fatty acids.
α-Vitamin E ((+)-α-Tocopherol) has proposed benefits for influenza virus A infection, as well as possible activity against hepatitis B and C. α-Vitamin E shows proviral effects, particularly in HEK293T/17 cells.

体内研究

α-Vitamin E ((+)-α-Tocopherol) prevents the increase in the pro-inflammatory cytokines IL-1, IL-6, and IFN-γ mRNA and protein compared with the ischemic-reperfused myocardium from untreated pigs and compared to the non-injured area.
α-Vitamin E (D-α-Tocopherol; intraperitoneal injection or oral administration) treatment induces an amelioration of diabetic nephropathy in mice through the activation of diacylglycerol kinase α (DGKα) and the prevention of podocyte loss.

分子式
C29H50O2
分子量
430.71
CAS号
59-02-9
中文名称
α-维生素 E;(+)-α-生育酚;D-α-生育酚
运输条件

Room temperature in continental US; may vary elsewhere.

储存方式

4°C, protect from light, stored under nitrogen

*In solvent : -80°C, 6 months; -20°C, 1 month (protect from light, stored under nitrogen)

溶解性数据
In Vitro: 

DMSO : 50 mg/mL (116.09 mM; Need ultrasonic)

H2O : < 0.1 mg/mL (ultrasonic) (insoluble)

配制储备液
浓度 溶剂体积 质量 1 mg 5 mg 10 mg
1 mM 2.3217 mL 11.6087 mL 23.2175 mL
5 mM 0.4643 mL 2.3217 mL 4.6435 mL
10 mM 0.2322 mL 1.1609 mL 2.3217 mL
*

请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效。
储备液的保存方式和期限:-80°C, 6 months; -20°C, 1 month (protect from light, stored under nitrogen)。-80°C 储存时,请在 6 个月内使用,-20°C 储存时,请在 1 个月内使用。

In Vivo:

请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照 In Vitro 方式配制澄清的储备液,再依次添加助溶剂:

——为保证实验结果的可靠性,澄清的储备液可以根据储存条件,适当保存;体内实验的工作液,建议您现用现配,当天使用; 以下溶剂前显示的百
分比是指该溶剂在您配制终溶液中的体积占比;如在配制过程中出现沉淀、析出现象,可以通过加热和/或超声的方式助溶

  • 1.

    请依序添加每种溶剂: 10% DMSO    40% PEG300    5% Tween-80    45% saline

    Solubility: ≥ 2.5 mg/mL (5.80 mM); Clear solution

    此方案可获得 ≥ 2.5 mg/mL (5.80 mM,饱和度未知) 的澄清溶液。

    以 1 mL 工作液为例,取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 400 μL PEG300 中,混合均匀;向上述体系中加入50 μL Tween-80,混合均匀;然后继续加入 450 μL生理盐水定容至 1 mL。

  • 2.

    请依序添加每种溶剂: 10% DMSO    90% (20% SBE-β-CD in saline)

    Solubility: 2.5 mg/mL (5.80 mM); Suspended solution; Need ultrasonic

    此方案可获得 2.5 mg/mL (5.80 mM) 的均匀悬浊液,悬浊液可用于口服和腹腔注射。

    以 1 mL 工作液为例,取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 900 μL 20% 的 SBE-β-CD 生理盐水水溶液中,混合均匀。

  • 3.

    请依序添加每种溶剂: 10% DMSO    90% corn oil

    Solubility: ≥ 2.5 mg/mL (5.80 mM); Clear solution

    此方案可获得 ≥ 2.5 mg/mL (5.80 mM,饱和度未知) 的澄清溶液,此方案不适用于实验周期在半个月以上的实验。

    以 1 mL 工作液为例,取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 900 μL玉米油中,混合均匀。

科研文献
The molarity calculator equation
Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)
The dilution calculator equation
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
This equation is commonly abbreviated as: C1V1 = C2V2
在线客服
咨询热线
400-881-9290
关注微信公众号